Screening for B cell clone prior to taking a JAK2 inhibitor suggested

June 15, 2018

Patients with a pre-existing B-cell clone in their bone marrow are more likely to develop lymphoma after taking a JAK2 inhibitor, a study from Austria has found. Heinz Gisslinger, MD, found that patients with this alteration in the B cell lineage, who had taken a JAK2 inhibitor, were 16 times more likely to develop B Cell Lymphoma compared to patients who did not have clonal B cells.​

Click here to read the report from Blood

This is something to discuss with your physician to ensure that you are adequately screened for all risk factors associated with having an MPN and any medication you are taking. 

Receive updates on the latest MPN news & events.

Find out ways you can help support MPN patients and researchers.

x

NEVER MISS AN UPDATE

Get free, timely information on living with an MPN.

Subscribe